Patients who wish to do so can participate in a clinical study. Here is a list of the current studies :

Digestive oncology (more info with Dr E Monsaert and Dr E Vanderstraeten)

  • ASPIRIN: Phase III double-blinded, placebo-controlled, randomised clinical trial to assess the effect of low-dose aspirin on relapse and survival in colorectal cancer patients.
  • Spotlight (ASTELLAS): Phase III, global, multi-centre, double-blind, randomised, efficacy study of zolbetuximab (IMAB362) plus mFOLFOX6 compared to placebo plus mFOLFOX6 as 1steline treatment in patients with claudin (CLDN)18.2 positive, HER2-negative, locally advanced non-resectable or metastatic gastric or junction adenocarcinoma.
  • Folicolor trial (UZA): Follow-up of treatment response using blood samples in metastatic colorectal cancer patients.

Crohn's Disease and/or Colitis Ulcerosa (more information with Dr D. Baert and Prof. Dr. P Dewint)

  • Rescue: Loss of response to Ustekinumab treated with dose escalation.
  • LATTICE (BMS): A randomised, double-blind, placebo-controlled phase II study on the safety and efficacy of BMS-986165 in test subjects with moderate-to-severe Crohn's disease.
  • Sequence M20-259 (Abbvie): A phase III, multicentric, randomised, efficacy assessor-blinded study of Risankizumab compared to Ustekinumab for the treatment of adult subjects with moderate to severe Crohn’s Disease who have failed anti-TNF therapy.
  • QUASAR (Janssen-Cilg): A multicentric, randomised, double-blind, placebo-controlled phase IIb/III study with parallel groups to evaluate the efficacy and safety of Guselkumab in participants with moderate-to-severe active ulcerative colitis.
  • Instruct-UC (Eli Lilly): An adaptive phase II, randomised, double blind, placebo-controlled study of LY3471851 (NKTR 358) in patients with moderately to severely active ulcerative colitis
  • MH002-UC-201 (MRM Health): Randomised, double-blind, placebo-controlled study to evaluate safety, mechanistic effects and effects on disease activities of MH002 in test persons with mild-to-moderate ulcerative colitis: a first-in-human study.

Endoscopic treatments (more information with Prof. Dr. P Dewint)

Scientific research is indispensable for the advancement of science. By participating in clinical studies, we are able to expand current treatment options and provided patients with access to the very latest treatments.


Non-alcoholic steatohepatitis (NASH) (more information with Prof Dr. C Van Steenkiste)

  • MGL-3196-11 (MADRIGAL): A phase III, multinational, double-blind, randomised, placebo-controlled study of MGL-3196 (resmetirom) in patients with non-alcoholic steatohepatitis (NASH) and fibrosis to eliminate NASH and limit progression to cirrhosis and/or liver compensation.
  • ESSENCE/NN9931-4553 (Novo Nordisk): The effect of semaglutide on test subjects with non-cirrhotic, non-alcoholic steatohepatitis.
  • GT-031 (Galectin): Study evaluating efficacy and safety of Belapectine (GR-MD-02) for the prevention of oesophagal varicoses in NASH cirrhosis.
  • 1404-0043 (Boehringer Ingelheim): Multicentric, double-blind, parallel-group, randomised, 48 weeks, dose-ranging, placebo-controlled phase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous doses of BI 456906 in patients with non-alcoholic steatohepatitis (NASH) and fibrosis

Alcoholic hepatitis (more information with Prof. Dr. C Van Steenkiste)

  • Cortisave: Evaluation of the efficacy of corticosteroids in the treatment of alcoholic hepatitis in spontaneous improvement.

Primary biliar cholangitis (more info from Prof. Dr. C Van Steenkiste)

  • RESPONSE (CymaBay Therapeutics): A placebo-controlled, randomised, phase III study about the effectiveness and safety of seladelpar in patients with primary biliar cholangitis (PBC) with an inadequate response to or intolerance for ursodeoxycholic acid (UDCA).

Clostridium difficile infection (more information from Prof. Dr C Van Steenkiste)

  • COIN-B (UZA): Controlled groups of antiviral treatments in chronic hepatitis B infections.

Non-Helicobacter pylori helicobacters (NHPH) (more info from Prof. Dr. C Van Steenkiste)

  • Evaluation of the prevalence and role of non-Helicobacter pylori helicobacters (NHPH) in defined risk populations.

Participation in these studies is on a voluntary basis and written consent is required. You are free to stop with them whenever you want, without this affecting further treatment and the relationship with your physician.